迪克科夫-1 (DKK1) 驱动割耐药前列腺癌的生长和转移
Letizia Rinella1, Gloria Fiorentino1, Mara Compagno2
1Department of Medical Sciences, University of Turin, Turin, Italy.
Cancer gene therapy
|May 13, 2024
概括
迪克科夫-1 (DKK1) 促进了转移性割抵抗性前列腺癌 (mCRPC) 的生长和传播. 在临床前模型中,抑制DKK1显著降低了瘤生长和转移.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 转移性割抵抗性前列腺癌 (mCRPC) 是一个严重的临床挑战,预后不佳.
- 确定mCRPC进展的分子驱动因素对于开发有效的治疗方法至关重要.
研究的目的:
- 研究Dickkopf-1 (DKK1),一个Wnt信号调节器,在mCRPC的生长和转移进展中的作用.
- 评估在mCRPC中针对DKK1的治疗潜力.
主要方法:
- 在PC3和DU145mCRPC细胞系中使用siRNA使DKK1沉默,并使用CRISPR/Cas9删除.
- 在体外测试评估了细胞生长,迁移,细胞循环和基因表达.
- 采用异种移植小鼠模型来评估瘤生长和肺转移的形成.
主要成果:
- 在体外,DKK1的沉默和删除减少了mCRPC细胞的生长和迁移.
- DKK1淘汰细胞显示细胞循环停止,改变的突蛋白和调节的转移相关基因,包括E-cadherin重新表达和Cadherin-11下调.
- 在体内,DKK1删除抑制了异种移植模型中的瘤生长和肺转移.
结论:
- DKK1在mCRPC的生长和转移传播中发挥着关键作用.
- 针对DKK1代表了对mCRPC的有前途的治疗策略.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K


